Trial Outcomes & Findings for A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine Products (NCT NCT05452278)
NCT ID: NCT05452278
Last Updated: 2026-03-09
Results Overview
Maximum observed plasma nicotine concentration
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
27 participants
Primary outcome timeframe
5 minutes prior to product use and 5, 10, 15, 20, 25, 30, 45, 60, 90 minutes, 2, 4, 6 and 8 hours post start of product use
Results posted on
2026-03-09
Participant Flow
Participant milestones
| Measure |
Product Sequence ABCD
Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence BCDA
Subjects use Product B on Day 1, Product C on Day 2, Product D on Day 3 and Product A on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence CDAB
Subjects use Product C on Day 1, Product D on Day 2, Product A on Day 3 and Product B on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence DABC
Subjects use Product D on Day 1, Product A on Day 2, Product B on Day 3 and Product C on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
7
|
7
|
7
|
6
|
|
Overall Study
COMPLETED
|
7
|
7
|
7
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine Products
Baseline characteristics by cohort
| Measure |
Product Sequence ABCD
n=7 Participants
Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence BCDA
n=7 Participants
Subjects use Product B on Day 1, Product C on Day 2, Product D on Day 3 and Product A on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence CDAB
n=7 Participants
Subjects use Product C on Day 1, Product D on Day 2, Product A on Day 3 and Product B on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Product Sequence DABC
n=6 Participants
Subjects use Product D on Day 1, Product A on Day 2, Product B on Day 3 and Product C on Day 4
Product A: Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
Product B: Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
Product C: Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
Product D: Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
|
Total
n=27 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
29.4 years
STANDARD_DEVIATION 10.2 • n=68 Participants
|
32.4 years
STANDARD_DEVIATION 14.4 • n=69 Participants
|
30.1 years
STANDARD_DEVIATION 10.0 • n=137 Participants
|
32.5 years
STANDARD_DEVIATION 15.0 • n=565 Participants
|
31.1 years
STANDARD_DEVIATION 11.8 • n=127 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=68 Participants
|
1 Participants
n=69 Participants
|
4 Participants
n=137 Participants
|
2 Participants
n=565 Participants
|
11 Participants
n=127 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=68 Participants
|
6 Participants
n=69 Participants
|
3 Participants
n=137 Participants
|
4 Participants
n=565 Participants
|
16 Participants
n=127 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
7 Participants
n=68 Participants
|
7 Participants
n=69 Participants
|
7 Participants
n=137 Participants
|
6 Participants
n=565 Participants
|
27 Participants
n=127 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=68 Participants
|
2 Participants
n=69 Participants
|
1 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
3 Participants
n=127 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
1 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
2 Participants
n=127 Participants
|
|
Race (NIH/OMB)
White
|
6 Participants
n=68 Participants
|
5 Participants
n=69 Participants
|
5 Participants
n=137 Participants
|
6 Participants
n=565 Participants
|
22 Participants
n=127 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
0 Participants
n=565 Participants
|
0 Participants
n=127 Participants
|
PRIMARY outcome
Timeframe: 5 minutes prior to product use and 5, 10, 15, 20, 25, 30, 45, 60, 90 minutes, 2, 4, 6 and 8 hours post start of product usePopulation: The analysis population represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
Maximum observed plasma nicotine concentration
Outcome measures
| Measure |
Product A
n=27 Participants
All subjects further to use of Product A
|
Product B
n=26 Participants
All subjects further to use of Product B
|
Product C
n=26 Participants
All subjects further to use of Product C
|
Product D
n=27 Participants
All subjects further to use of Product D
|
|---|---|---|---|---|
|
Nicotine Cmax
|
14.98 ng/mL
Standard Deviation 4.96
|
13.43 ng/mL
Standard Deviation 4.97
|
19.35 ng/mL
Standard Deviation 6.58
|
13.85 ng/mL
Standard Deviation 3.85
|
PRIMARY outcome
Timeframe: 5 minutes prior to product use and at 5, 10, 15, 20, 25, 30, 45, 60, 90 minutes, 2, 4, 6 and 8 hours post start of product usePopulation: The analysis population represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
The area under the concentration-time curve for nicotine, from time 0 to the time of the last sampling timepoint
Outcome measures
| Measure |
Product A
n=27 Participants
All subjects further to use of Product A
|
Product B
n=26 Participants
All subjects further to use of Product B
|
Product C
n=26 Participants
All subjects further to use of Product C
|
Product D
n=27 Participants
All subjects further to use of Product D
|
|---|---|---|---|---|
|
Nicotine AUCt
|
36.48 h*ng/mL
Standard Deviation 12.72
|
31.72 h*ng/mL
Standard Deviation 9.50
|
48.44 h*ng/mL
Standard Deviation 19.68
|
32.11 h*ng/mL
Standard Deviation 9.46
|
SECONDARY outcome
Timeframe: 20 minutesPopulation: The analysis population represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
The percentage of orally extracted nicotine from each pouch after 20 minutes of product use is calculated by subtracting the amount of nicotine left in the study pouches after use, to the amount of nicotine in unused reference pouches. Extracted dose of nicotine was assessed by the formula: (A\*B)/C - D where A = Reference value of nicotine as assessed by the average of extracted nicotine in unused reference pouches B = Weight of the unused pouch C = Reference weight value as assessed by the average of weight for unused reference pouches D = Extracted nicotine of the used pouch
Outcome measures
| Measure |
Product A
n=27 Participants
All subjects further to use of Product A
|
Product B
n=27 Participants
All subjects further to use of Product B
|
Product C
n=27 Participants
All subjects further to use of Product C
|
Product D
n=27 Participants
All subjects further to use of Product D
|
|---|---|---|---|---|
|
Percentage of Orally Extracted of Nicotine
|
19.10 Percentage of nicotine
Standard Deviation 9.98
|
22.9 Percentage of nicotine
Standard Deviation 10.3
|
21.9 Percentage of nicotine
Standard Deviation 9.77
|
14.0 Percentage of nicotine
Standard Deviation 4.63
|
SECONDARY outcome
Timeframe: 5 minutes prior to product use and at 5, 10, 15, 20, 25, 30, 45 minutes, and 1, 1.5, 2, 4, 6 and 8 hours post start of product usePopulation: The analysis population represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
The subjects will self-assess their urge to use a nicotine pouch, pre-use and after use, by answering the question: "How strong is your urge to use a nicotine pouch right now?" on a 100 mm visual analogue scale (VAS), with the anchor points 0 mm (= not at all/no urge) and 100 mm (= extremely/extreme urge). Emax is the maximum change from baseline VAS score (VASpre-use - VASpost-use).
Outcome measures
| Measure |
Product A
n=27 Participants
All subjects further to use of Product A
|
Product B
n=27 Participants
All subjects further to use of Product B
|
Product C
n=25 Participants
All subjects further to use of Product C
|
Product D
n=26 Participants
All subjects further to use of Product D
|
|---|---|---|---|---|
|
Urge to Use Emax
|
61.7 mm
Standard Deviation 23.3
|
57.7 mm
Standard Deviation 19.7
|
66.1 mm
Standard Deviation 22.4
|
52.7 mm
Standard Deviation 25.7
|
Adverse Events
Product A
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Product B
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Product C
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Product D
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Product A
n=27 participants at risk
All subjects further to use of Product A
|
Product B
n=27 participants at risk
All subjects further to use of Product B
|
Product C
n=27 participants at risk
All subjects further to use of Product C
|
Product D
n=27 participants at risk
All subjects further to use of Product D
|
|---|---|---|---|---|
|
Eye disorders
Photophobia
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
General disorders
Fatigue
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Gastrointestinal disorders
Constipation
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Gastrointestinal disorders
Nausea
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Gastrointestinal disorders
Vomiting
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
7.4%
2/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Nervous system disorders
Dizziness
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
|
Nervous system disorders
Headache
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
14.8%
4/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
3.7%
1/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
0.00%
0/27 • 7 days
The number of participants at risk represents all subjects who used a specific product. The overall number of participants analyzed for each product is therefore different from the number of participants in each arm provided in the Participant Flow module.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place